clinical trials

Shingles vaccine market poised for robust growth through 2036 driven by aging populations, vaccine adoption, and emerging candidates challenging market leader SHINGRIX.

Novo Nordisk leads GLP-1 market but faces Eli Lilly competition; Amgen's MariTide offers differentiated approach with less portfolio risk.

AIM ImmunoTech closes $1.8M rights offering to advance Ampligen immunotherapy development for late-stage pancreatic cancer treatment.

Jade Biosciences reports $127.4M full-year loss, maintains $336.2M cash runway through mid-2028 with pipeline data catalysts starting Q2 2026.

Iovance shows 60.6% fiscal 2025 revenue growth for its personalized cancer therapy Amtagvi, but faces manufacturing complexity and profitability challenges ahead.

Global GLP-1 receptor agonist market projected to grow from $70B in 2025 to $202B by 2033 at 12.78% annual rate, driven by obesity and diabetes prevalence.

Oculis plans March 2026 investor conferences highlighting six pivotal clinical readouts, including Privosegtor's breakthrough optic neuritis program and OCS-01 Phase 3 results expected Q2 2026.

Oculis announces March 2026 investor conference participation, showcasing pipeline advances including Privosegtor's optic neuritis breakthrough designation and anticipated Phase 3 readouts.

Vertex Pharmaceuticals offers profitable gene-editing exposure versus CRISPR's pipeline-dependent model. Casgevy's slow adoption and high costs make Vertex's diversified, profitable business more attractive for risk-averse investors despite lower upside potential.

Rezolute to present ersodetug antibody therapy program at Citizens Life Sciences Conference in Miami, March 10-11, 2026, with direct investor meetings.

Grabar Law Office investigates shareholder claims against $CORT, $ITGR, $KD, and $MOH for alleged disclosure failures and fiduciary breaches spanning clinical trials, sales concealment, and cost trend non-disclosure.

Cell therapy companies achieve major manufacturing and clinical milestones, positioning sector for explosive growth as global market targets $8.2 billion by 2026.

Royal Philips coordinates seven clinical trials across Europe to validate AI-assisted robotics for brain and liver tumor treatments, addressing physician shortages.

Acute ischemic stroke market poised for significant growth through 2036, driven by novel therapies including recently approved tenecteplase and promising pipeline candidates addressing 1.8 million annual cases.

Rallybio soars as merger with $505M-backed Candid Therapeutics creates combined biotech with $700M cash runway through 2030.

NRx Pharmaceuticals appoints Prof. Joshua Brown, leading TMS researcher, as Chief Medical Innovation Officer to advance PTSD and depression treatments for veterans.

uniQure's $QURE stock crashes 49% after FDA rejects Huntington's gene therapy approval pathway; securities fraud lawsuit filed alleging misleading statements about regulatory expectations.

Pfizer's reasonable valuation, robust pipeline, and 6.4% dividend yield offer disciplined returns versus speculative biotech like Regencell, whose 21,000% surge lacks fundamental justification.

Exelixis secures FDA approval for zanzalintinib and expands beyond cabozantinib with robust pipeline, posting 57.9% EPS growth while advancing multiple Phase 3 trials.

Corcept Therapeutics faces securities lawsuit alleging misrepresentation of relacorilant clinical data and FDA approval prospects, while withholding known regulatory risks from investors.